Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

Cryopyrin-associated Periodic Syndromes Clinical Trial

Official title:

An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00991146
• Other study ID #: CACZ885D2308
• Status: Completed
• Phase: Phase 3
• Start date: October 2009
• Est. completion date: February 2012

Study information

• Verified date: September 2020
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To date there are no approved effective therapies for the treatment of cryopyrin-associated periodic syndromes (CAPS) including Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), or Neonatal Onset Multisystem Inflammatory Disease (NOMID) in Japan.

The study will assess the efficacy and safety of canakinumab in Japanese patients with cryopyrin-associated periodic syndromes (CAPS). In previous and currently ongoing CAPS studies (CACZ885A2102, CACZ885D2201, CACZ885D2304, CACZ885D2306), it has been observed that treatment with canakinumab in patients with CAPS contributed to ensure absence of relapse, to improve signs and symptoms and to prevent secondary disease complications. However, no Japanese patients have been included in those studies. This study will allow access for Japanese patients to a new potentially efficacious treatment for CAPS patients with a convenient dosing regimen.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: February 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

1. At study entry, patients should have a clinical diagnosis of FCAS, MWS or NOMID and require medication. At the time of screening, patients can be either untreated or treated with other medication.

2. Presence, or history of at least 2 of the following symptoms:

• For NOMID patients:

• Typical NOMID urticarial rash

• Signs of central nervous system (CNS) involvement such as increased intracranial pressure and/or papilledema and/or cerebral spinal fluid pleiocytosis and/or stroke and/or seizures, and/or sensorineural hearing loss

• Typical arthropatic changes on X-rays: epiphysal and/or patellar overgrowth With start of NOMID symptoms before or at 6 months of age

• For MWS patients:

• periodic fever

• headache/migraine

• arthralgia

• urticarial skin rash

• conjunctivitis

• myalgia

• sensorineural hearing impairment

• For FCAS patients:

• urticarial skin rash

• fever/chills

• conjunctivitis

• joint pain

3. Patients requiring oral steroids, NSAIDs and/or disease-modifying antirheumatic drugs (DMARDs) can be enrolled if they are on a stable dose (oral steroids: < 20 mg/day or < or = 0.4 mg/kg prednisone or prednisone equivalent, whichever applies) for at least 4 weeks prior to the screening visit.

4. Able to communicate with the investigator and comply with the requirements of the study (for children the parent can assist when necessary).

Exclusion Criteria:

1. Pregnant or nursing (lactating) women.

2. All women capable of becoming pregnant unless they are postmenopausal or are using one or more methods of contraception.

3. Participation in any other study within 30 days

4. Infection with HIV, Hepatitis B or C.

5. Live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose.

6. History of drug or alcohol abuse within the 12 months prior to dosing.

7. Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing for adults.

8. History of significant medical conditions, which in the doctor's opinion would exclude the patient from participating in this trial.

9. History of renal transplantation.

10. Presence of any additional rheumatic diseases or significant systemic diseases. For example, major chronic infectious/ inflammatory/ immunologic disease (such as inflammatory bowel disease, psoriatic arthritis, spondyloarthropathy, systemic lupus erythematosus in addition to the autoinflammatory disease).

11. Presence of any of the following laboratory abnormalities: ALT or AST greater than 2 times the upper limit of normal (ULN), platelet count less than 100x109/L.

12. History of recurrent and/or evidence of clinically significant active bacterial, fungal, or viral infections.

13. History of contact with patients with suspected tuberculosis symptoms; or history or complication of tuberculosis infection.

14. Use of the following therapies:

• Etanercept in the 4 weeks prior to the baseline visit (Day 1) and thereafter

• Adalimumab in the 8 weeks prior to the baseline visit (Day 1) and thereafter

• Infliximab in the 12 weeks prior to the baseline visit (Day 1) and thereafter

• Rituximab in the 26 weeks prior to the baseline visit (Day 1) and thereafter

• Tocilizumab in the 3 weeks prior to the baseline visit (Day 1) and thereafter

• Any other investigational biologics in the 8 weeks prior to the baseline visit (Day 1) and thereafter (with the exception of anakinra therapy-see below)

• Anakinra therapy after the baseline visit (Day 1). Last anakinra injection should occur not less than 6 hours prior to the canakinumab injection at Day 1

• Leflunomide in the 4 weeks prior to the baseline visit (Day 1) and thereafter. After the completion of leflunomide treatment a cholestiramine in dose 8 g 3 times per day for 14 days is recommended.

• Thalidomide in the 4 weeks prior to the baseline visit (Day 1) and thereafter

• Cyclosporine in the 4 weeks prior to the baseline visit (Day 1) and thereafter

• i.v. immunoglobulin (i.v. Ig) in the 8 weeks prior to the baseline visit (Day 1) and thereafter

• 6-Mercaptopurine, azathioprine, cyclophosphamide, or chlorambucil in the 12 weeks prior to the baseline visit (Day 1) and thereafter

• Dapsone, mycophenolate mofetil in the 3 weeks prior to the baseline visit (Day 1) and thereafter

• > or = 20 mg/day or >0.4 mg/kg, whichever applies, of prednisone or prednisone equivalent in the 4 week prior to the baseline visit (Day 1) and thereafter

• Methyl prednisone pulse therapy in the 4 weeks prior to baseline visit and thereafter

15. History of allergic reaction to similar drugs. No additional exclusions may be applied by the doctor, in order to ensure that the study population will be representative of all eligible patients.

Other protocol-defined inclusion/exclusion criteria may apply

Related Conditions & MeSH terms

• Cellulitis
• Cryopyrin-Associated Periodic Syndromes
• Eosinophilia
• Familial Cold Autoinflammatory Syndrome
• Muckle-Wells Syndrome
• Neonatal Onset Multisystem Inflammatory Disease
• Syndrome

Intervention

Drug:
• canakinumab
canakinumab

Locations

Country	Name	City	State
Japan	Novartis Investigative Site	Fukuoka-city	Fukuoka
Japan	Novartis Investigative Site	Kyoto-city	Kyoto
Japan	Novartis Investigative Site	Yokohama-city	Kanagawa

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Imagawa T, Nishikomori R, Takada H, Takeshita S, Patel N, Kim D, Lheritier K, Heike T, Hara T, Yokota S. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-lab — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants without a relapse		24 weeks
Secondary	Number of complete responder patients		29 days
Secondary	Clinical improvement (or resolution) with regards to: central nervous system (CNS) involvement, eye disease, hearing impairment, skin disease, joint disease, fever, and kidney function		24 months
Secondary	Number of patients experiencing a relapse during the entire study		24 months
Secondary	How much canakinumab is contained in the patients' blood (pharmacokinetics) and what are the effect of canakinumab on the patients' body (pharmacodynamic)		24 months
Secondary	Presence of antibody against canakinumab		24 months

External Links

•   Results for CACZ885D2308 from the Novartis Clinical Trials website